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Head of bed elevation to relieve
gastroesophageal reflux symptoms: a
systematic review
Loai Albarqouni1* , Ray Moynihan1, Justin Clark1, Anna Mae Scott1, Anne Duggan2 and Chris Del Mar1
Abstract
Background: Overuse of proton pump inhibitors (PPIs) – frequently used for relieving symptoms of
gastroesophageal reflux disease (GORD) – raises long-term safety concerns, warranting evidence-based non-drug
interventions. We conducted a systematic review to evaluate the effect of head-of-bed elevation on relieving
symptoms of GORD in adults.
Methods: We included controlled trials comparing the effect of head-of-bed elevation interventions to control in
adults with GORD. Two independent reviewers screened articles, extracted data, and assessed quality of included
studies. Primary outcomes were changes in GORD symptoms and use of PPIs.
Results: We screened 1206 records; and included five trials (four cross-over and one factorial) comprising 228
patients. All five included trials were judged to be at high-risk of performance bias and four of selection bias. Of five
included trials, two used ‘bed blocks’ under the bed legs; one used ‘sleeping on a wedge’ pillow, and two used
both. High heterogeneity in outcome measures and reported outcomes data precluded meta-analyses. The four
studies that reported on GORD symptoms found an improvement among participants in the head-of-bed elevation;
a high-quality crossover trial showed a clinical important reduction in symptom scores at 6 weeks (risk ratio of 2.1;
95% CI 1.2 to 3.6). These results are supported by the observed improvement in physiological intra-oesophageal pH
measurements.
Conclusions: Methodological and reporting limitations in available literature preclude definitive recommendations.
However, head-of-bed elevation could be still considered as a cheap and safe alternative to drug interventions with
unfavourable safety profiles.
Protocol registration: Open Science Framework: http://osf.io/2hz3j
Keywords: GORD, Non-pharmacological interventions, Proton pump inhibitors, General practice
Background
Proton pump inhibitors (PPIs) are among the most com-
monly prescribed medications worldwide [1]. PPIs are
usually prescribed to treat common upper gastrointes-
tinal symptoms often diagnosed as Gastroesophageal
Reflux Disease, GORD (i.e. also known as GERD or re-
flux disease) [2]. While PPIs are effective at controlling
these symptoms, there is evidence of great variation in
prescribing rates [3], and widespread overuse (e.g. with
estimates that between one-quarter and two-thirds of
patients may be taking them inappropriately) [1, 4–6].
Long term use of PPIs has been linked to a potential
increased risk of fractures [7, 8]; pneumonia [9]; and
Clostridium difficile infection [10]. Many deprescribing
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initiatives are underway to reduce the use of PPIs [1,
11]. Against this backdrop of concern about widespread
overuse, patient harm and waste, it is timely to investi-
gate the evidence supporting non-drug interventions for
the symptoms of GORD [12, 13].
Gastrointestinal symptoms such as heartburn, dyspep-
sia, and regurgitation are common - one-in-five adults
report one of these symptoms at some point in their
lives [14]; and they are a very common reason for pri-
mary care consultations [15]. Although these symptoms
are highly prevalent and can be mild or transient, adults
experiencing these symptoms are often diagnosed with
GORD. Guidelines recommend a stepwise approach for
managing GORD symptoms, beginning with non-drug
interventions including lifestyle modifications (e.g.
weight loss, smoking cessation, and avoiding late or
evening meals), and progressing to drug and surgical
interventions when needed [2, 16]. However, the wide-
spread use of drug interventions such as PPIs has
rendered non-drug interventions underused and unfash-
ionable, and its full potential as an effective addition or
alternative to drug interventions has been under-
researched and under-utilised [17].
One promising, easy-to-adopt, non-drug intervention
is elevating the head of the bed, which may also be used
to avoid, or to lower the dose required of PPIs [12]. A
potential mechanism of action is by reducing the
oesophageal exposure to stomach acid and increasing
the clearance of acid from the oesophagus [18]. Trials
have been conducted to evaluate this simple intervention
[19, 20], however, we are unaware of any recent high
quality systematic review summarizing evidence to in-
form practice. The aim of this study was to do a system-
atic review of controlled trials that evaluated the effect
of head-of-bed elevation or positioning on relieving
GORD symptoms among adults.
Methods
Design
This systematic review is reported following the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [21]. and the review
protocol was developed prospectively and registered on
the Open Science Framework (osf.io/2hz3j).
Eligibility criteria
Participants
We included studies of adults with symptoms suggestive
of GORD (of any severity and as diagnosed in each
study).
Interventions
We included studies evaluating change of the head-of-
bed position interventions including (i) head-of-bed
elevation (either by sleeping on a wedge pillow – ‘sleep-
ing on a wedge’ – or raising the legs of the head of the
bed by blocks - ‘bed blocks’); (ii) left lateral sleep pos-
ition; (iii) or both. Studies evaluating interventions of
interest together with co-interventions (e.g. PPIs) were
included, as long as the effect of the intervention of
interest could be isolated (e.g. head-of-bed elevation plus
PPIs vs PPIs alone).
Comparators
We included studies where the comparator was control
(i.e. no change to head-of-bed elevation e.g. flat position)
or right lateral sleep position.
Outcomes
Primary outcomes were changes in GORD symptoms
and use of PPIs. Secondary outcomes included physio-
logical measurements of intra-oesophageal pH (e.g. acid
exposure/reflux episodes), disease progression, and ad-
verse events.
Study design We included randomized and non-
randomized controlled trials (RCTs and non-RCTs). We
excluded before-after studies with no control group, ob-
servational studies, and review articles. We included
publications available as abstract only (e.g. conference
abstract) only if they reported adequate information re-
quired for inclusion.
Search strategies to identify studies
One of the authors, a senior information specialist (JC),
searched PubMed, Embase, Cochrane CENTRAL and
CINAHL (from inception until 23 June 2020). The
search string was designed for PubMed and translated
for use in other databases using the Polyglot Search
Translator [22]. The complete search strings for all data-
bases are provided in Appendix 1. We also searched
clinicaltrials.gov and World Health Organization’s Inter-
national Clinical Trials Registry Platform (via the
Cochrane Library on 23 June 2020) for any relevant reg-
istered ongoing or unpublished trials. We supplemented
our database searches with a forwards and backwards
citation search of all included studies in Scopus database
(on 25 June 2020). No restrictions by language or publi-
cation date were imposed.
Study selection and screening
Two review authors (LA, RM) independently screened
the titles and abstracts for inclusion against inclusion
criteria; one author (JC) retrieved full texts, and two au-
thors (LA, RM) screened the full texts for inclusion. Any
disagreements were resolved by discussion, or referred
to a third author (AD, CDM).
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Data extraction and risk of bias assessment
Two review authors (LA, RM) independently extracted
data into a prespecified, pilot-tested data extraction form
– including the following data on study characteristics;
participants; interventions; comparisons; and outcomes.
Two review authors (LA, RM) independently assessed
the risk of bias for each included study using the
Cochrane Collaboration’s tool for assessing risk of bias
[23]. Any disagreements were resolved by discussion or
by referring to a third author (AD or CDM).
Data synthesis
We could not undertake meta-analyses because it was
not possible or appropriate (i.e. no sufficient comparable
data measuring the same outcome). Therefore, we syn-
thesized the results narratively, reporting the results for
each outcome separately – following the Synthesis with-
out meta-analysis (SWiM) in systematic reviews guid-
ance [24]. For continuous outcomes, we used mean
difference (with 95% CIs) or standardized mean differ-
ence, as appropriate. For dichotomous outcomes, we
used risk ratios (with 95% CIs) for results reporting the
number of people with an event, as appropriate.
Results
We identified 1256 records through database searching
and 356 through forward-backward citation analysis for
a total of 1206 records to screen after deduplication. We
excluded 1181 records after screening titles and ab-
stracts and obtained 25 records for full-text screening.
We excluded 20 full-text articles with reasons for exclu-
sion recorded. (Fig. 1) We also screened 36 clinical trial
registries and found one relevant trial that we already
identified in database searches. We included five studies
in the narrative synthesis.
Characteristics of included studies
Of all the five included randomised controlled trials, two
were conducted in the United Kingdom [25, 26], with
the others in the United States [27], Taiwan [28], and
Columbia [29] (Table 1). Three studies were published
in the 1970s and 1980s [25–27], with the two most re-
cent published in 2019 and 2020 [28, 29]. All studies
were small, with total number of participants ranging
from 14 to 71, and were of short-term duration, with the
longest intervention being for 6 weeks [26, 29]. Four
studies were cross-over trials [25, 27–29] and one was a
factorial RCT [26]. All trials had participants with
Fig. 1 PRISMA flow diagram of included articles
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gastroesophageal reflux symptoms, with one trial con-
ducted among participants who had previously had
oesophageal cancer and undergone esophagectomy and
gastric tube reconstruction [28]. All included studies
were reported in English except for one reported in
Spanish, which was also reported in English in clinical-
trials.gov (NCT02706938) [29].
In terms of intervention details (i.e. how elevation was
achieved), two trials used ‘bed blocks’ (i.e. 20 cm blocks
under the legs of the head of the bed) [26, 29], one trial
used ‘sleeping on a wedge’ (i.e. sleeping on a 20 cm
wedge-shaped pillow) [28], and two trials used both in-
terventions i.e. 20-28 cm ‘bed blocks’ and ‘sleeping on a
wedge’ (as two separate intervention arms) [25, 27].
None of the included studies evaluated the left lateral
sleep position as an intervention.
Risk of bias assessment
All five included studies were judged to be at high risk
in two or more of the domains of risk of bias. All five
studies were judged to be at high risk of performance
bias (either blinding of patients and personnel or
outcome assessors), and four at high or unclear risk for
selection bias (either random sequence generation or al-
location concealment) (Fig. 2).
Main findings
Heterogeneity, especially of outcome measures and the
reporting of outcome data, precluded meta-analyses of
the primary and secondary outcomes. Therefore, we re-
ported the results narratively grouped for each outcome
(Table 2).
Gastroesophageal reflux symptoms
All the four (of the five included) studies that we identi-
fied evaluating the impact of head of bed elevation on
patient-reported gastroesophageal reflux symptoms
found an improvement among participants in the head-
of-bed elevation intervention arm [25, 26, 28, 29].
A crossover randomized trial analysed the change in
GORD symptoms among 39 participants (out of the 65
enrolled participants) at 6 weeks using a 6-point scale,
the Reflux Disease Questionnaire Score, with a higher
score meaning a worse outcome and a change of ≥0.6
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65 participants with GORD-associated
sleep disturbance recruited from a hos-
pital outpatient unit with mean age of
56 years
Bed blocks + PPIs and/or
sodium alginate
Head-of-bed elevation for 6
weeks at home using 20 cm
















14 participants with oesophageal
cancer and nocturnal reflux symptoms
or reflux esophagitis, recruited from
hospital database, with mean age of
62 years
Sleeping on a Wedge + PPIs
Using a 20 cm high wedge-
shaped pillow at home (with
an elevation angle of 20 de-














15 participants with chronic reflux
symptoms and endoscopic evidence of
erosive esophagitis, recruited from
hospital outpatients, aged between 51
and 74 years
Sleeping on a Wedge
Using a 25 cm high foam
wedge (with an elevation
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71 participants with severe gastro-
oesophageal reflux, recruited from a
hospital, with a median age of 59 years
Bed blocks
Head-of-bed raised on 20
cm blocks (with 10%















63 participants with typical symptoms
of Gastroesophageal reflux, recruited




28 cm blocks during part of
the night
Sleeping on a Wedge
Sitting propped up during













aFactorial RCT – 2 factors ranitidine and head-of-bed elevation. bAll groups in hospital and for each group a pillow was allowed
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points considered clinically meaningful [29]. The trial
found that participants in the head-of-bed elevation
group were more likely to report a clinically meaningful
change of ≥10% in their symptom scores at 6 weeks
compared to the participants in the control group (27
[69%] versus 13 [33%], risk ratio of 2.1; 95% CI 1.2 to
3.6); with a mean difference in change scores of − 1.3,
95% CI − 2.0 to − 0.6).
A crossover trial of 63 participants [25], evaluating the
effect of head-of-bed elevation using ‘bed blocks’ or
‘sleeping on a wedge’, found a reduction in the number
of reflux symptoms (i.e. heartburn or acid regurgitation)
reported during the intervention (i.e. half-night) in the
head-of-bed elevation arm (mean difference in ‘bed
blocks’ -1, 95% CI − 2.2 to − 0.1; and ‘sleeping on a
wedge’ -1, 95% CI − 1.9 to − 0.01) compared to the con-
trol group.
A factorial RCT [26], evaluating the effect of ranitidine
and head-of-bed elevation among 71 participants, found
that participants in the head-of-bed elevation group were
more likely to report an overall improvement in their
symptoms at 6 weeks compared to the control group
(72% [23 of 32] vs. 55% [17 of 31]; unadjusted odds ratio
2.1, 95% CI 0.7 to 6.0; odds ratio adjusted for ranitidine
use 3.1, p < 0.005). It also found a reduction in the re-
ported scores, measured on a 4-point-scale, of gastro-
esophageal reflux and retrosternal pain symptom in the
head-of-bed elevation group compared to the control
group. There was no statistically significant difference in
overall improvement of symptoms reported by adults
receiving the head-of-bed elevation only compared to
adults receiving ranitidine only (59% [10 of 17] head-of-
bed elevation only vs. 77% [13 of 17] ranitidine only; RR
0.8, 95% CI 0.5 to 1.2).
Another crossover trial measured the change in GORD
symptoms among 14 post-esophagectomy participants at
2 weeks on a 30-point score, the modified Dysfunction
after Upper Gastrointestinal Surgery scale, with a higher
score meaning a worse outcome [28]. It found a statisti-
cally significant improvement in GORD symptoms in
the head-of-bed elevation group compared to the control
group (mean difference in change scores − 5.1, 95% CI
− 7.6 to − 2.6).
Intra-oesophageal pH measurement
We identified two trials evaluating the impact of head-
of-bed elevation using ‘bed blocks’ or ‘sleeping on a
wedge’ on the intra-oesophageal pH measurement (i.e.
reported as the number of reflux episodes; percent of
total time pH remained < 4; and acid clearance time)
[25, 27].
A cross-over RCT of 15 participants [27], found a sta-
tistically significant reduction in acid exposure (defined
as percent of total time intra-oesophageal pH remained
≤4) in both groups (mean % of total time: ‘sleeping on a
wedge’ 15, 95% CI 3 to 26; ‘bed blocks’ 15, 95% CI 0 to
31; control 21, 95% CI 10 to 33); but not in the number
of reflux episodes (defined as the total number of
occasions of intra-oesophageal drop to < 4) and acid
clearance time (defined as the total time that intra-
Fig. 2 Risk of bias assessment in included studies both in individual studies and domains (left) and in summary (right)
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higher score meaning a worse




Mean difference (MD) in change
scores at 6 weeks of 1.327, 95% CI
0.626 to 2.027.
27 of 39 [69.2%] participants in
the head-of-bed elevation group
were more likely to report a clinic-
ally meaningful change of ≥10%
in their symptom scores at 6
weeks compared to 13 [33.3%] in
the control group. Risk ratio (RR)
of 2.08; 95% CI 1.19 to 3.61).
NR 63.2% (95% CI 50.6 to
75.7%) of the 57 participants
preferred the head of bed
elevation to control.
39 of 63 participants in head-of-
bed elevation group reported
adverse events at 14 weeks com-
pared to none on the control
group (of 54): 20 bed slipping; 4
bed unsteadiness; 10 varicose
vain pain; 7 musculoskeletal
pain; and 1 sexual activity inter-







Modified Dysfunction after Upper
Gastrointestinal Surgery, a 30-
point score, with higher scores
means better outcomes.
Findings (improved)
MD in change scores at 2 weeks









Acid exposure, defined as percent
of total time intra-oesophageal
pH remained ≤4; Reflux episodes,
defined as drop of intra-
oesophageal pH to < 4; Acid clear-
ance time, defined as the total
time that intra-oesophageal pH <
4 by the number of reflux
episodes.
Findings (improved)
A reduction in acid exposure in
both sleeping on a wedge
(mean% 14.8, 95% CI 12.2 to 17.5
vs control: 21.2, 95% CI 18.4 to
23.7) and head-of-bed elevation
groups (mean% 15.3, 95% CI 11.7
to 18.8 vs control: 21.2, 95% CI
18.4 to 23.7) compared to the
control. A non-statistically signifi-
cant reduction in the number of
reflux episodes and acid clearance
time in any of the two groups
compared to the control.
60% (9 of 15) preferred
head-of-bed elevation,
33.3% (5 of 15) preferred
sleeping on wedge, and










An overall improvement in
symptoms and a 4-point-sclae of
gastroesophageal reflux, retro-
sternal pain, epigastric pain, and
dysphagia.
Findings (improved)
23 of 32 [71.9%] participants in
the head-of-bed elevation group
are more likely to report an overall
improvement in symptoms at 6
weeks compared to 17 of 31
[54.8%] - unadjusted OR 2.1, 95%
CI 0.74 to 5.99; adjusted OR 3.1,
NR NR 2 of 32 participants in the head-
of-bed elevation group reported
adverse events both resolved
and neither discontinued: 1 bed
slipping and 1 sexual activity
interference.
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oesophageal pH remained < 4 by the number of reflux
episodes) in any of the two groups compared to the con-
trol group.
In addition to measuring GORD symptoms [25], par-
ticipants in the ‘bed blocks’ arm in a cross-over study
had statistically significant reductions in acid exposure
(mean difference in % of total time that intra-
oesophageal pH remained < 4, − 7.3, 95% CI − 13.9 to −
0.7) and reflux episodes (mean difference in number of
drops in intra-oesophageal pH by two per participants,
− 2.5, 95% CI − 4.2 to − 0.8) compared to participants in
the control arm. But there were no statistically signifi-
cant reductions neither in acid exposure (mean differ-
ence in % of total time, 1.2, 95% CI − 3.9 to 6.3) nor in
reflux episodes (mean difference in number of episodes
per participants, − 0.6, 95% CI − 2.3 to 1.1) among par-
ticipants in the ‘sleeping on a wedge’ compared to the
control.
Patient preferences
We identified two studies that measured patient prefer-
ences for head-of-bed elevation using ‘bed blocks’ or
‘sleeping on a wedge’. [27, 29] In a crossover trial [29], 36
of the 57 participants (63, 95% CI 51 to 76%) preferred
the head-of-bed elevation to control intervention. Of the
15 participants included in another trial [27], 9 (60%)
preferred ‘bed blocks’; 5 (33%) preferred ‘sleeping on a
wedge’; and one (7%) preferred neither.
Adverse events
We identified two trials reporting adverse events associ-
ated with the intervention [26, 29]. A 2020 crossover
RCT found that 39 of 63 participants (62%) in head-of-
bed elevation group reported largely minor adverse
events at 14 weeks compared to no one in the control
group (24 bed-related e.g. bed slipping and unsteadiness;
and 15 others e.g. varicose vain pain, musculoskeletal
pain, and sexual activity interference) [29]. A factorial
RCT found that two of 32 participants in the head-of-
bed elevation group reported adverse events (one bed
slipping and one sexual activity interference); both re-
solved and neither discontinued the intervention [26].
Discussion
Summary
We found five eligible controlled trials, evaluating the ef-
fect of head-of-bed elevation on GORD. Overall, the re-
sults suggest that head-of-bed elevation may have a







X2 = 4, p < 0.005.
A statistically significant reduction
in symptom scores of
gastroesophageal reflux and
retrosternal pain but not








Number of reflux symptoms (i.e.
heartburn or acid regurgitation)
Findings (improved)
Compared to control group, a
statistically significant reduction in
the number of reflux symptoms
during the intervention (6 h) in
the head-of-bed elevation group
(2.0 ± 1.2 vs. 3.0 ± 2.4) and sleep-
ing on a wedge groups (2.4 ± 1.4
vs. 3.4 ± 2.2).
Outcome measures
Acid exposure, defined as percent
of total time that intra-esophageal
pH remained < 4; Reflux episodes,
defined as a drop in intra-
esophageal pH by 2; Acid clear-
ance time, defined as the total




reductions in acid exposure and
reflux episodes in the head-of-bed
elevation group (acid exposure:
6.7 ± 7.6; reflux episodes per par-
ticipant: 3.7 ± 1.9) compared to
control group (acid exposure:
14.0 ± 15.3; reflux episodes per
participant: 6.2 ± 3.9) but no sig-
nificant difference in sleeping on
a wedge group compared to con-
trol group in terms of acid expos-
ure (7.7 ± 11.7 vs 8.9 ± 9.7) and
reflux episodes (5.4 ± 3.8 vs. 4.8 ±
3.2).
NR NR
Abbreviations: NR Not reported, RCT Randomized controlled trial, CI Confidence interval, RR Risk ratio, OR Odds ratio
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beneficial effect on relieving gastroesophageal reflux
symptoms. These results are supported by the observed
improvement in physiological intra-oesophageal pH
measurements. However, methodological and reporting
issues limit the conclusions that can be drawn on the
impact of head-of-bed elevation.
Strengths and limitations
There are several limitations to our findings. The key
limitation to our systematic review was the very small
pool of existing evidence, and the poor quality and inad-
equate reporting of included trials. Most trials had small
sample sizes and were of limited duration – none longer
than 6 weeks – with considerable variations in the out-
come measures, which precluded meta-analyses of the
results from included studies. However, these are fre-
quently reported challenges in trials evaluating non-drug
interventions [30, 31]. The strengths of this review in-
clude its exhaustive search of multiple databases; inclu-
sion of non-English language trials (i.e. minimising risk
of language bias); rigorous quality assessment; and ad-
herence to the Cochrane methodological standards [32]
and PRISMA reporting guidance [33].
Comparison with existing literature
A 2006 systematic review of lifestyles measures for gas-
troesophageal reflux [12] identified full reports from just
two trials of head-of-bed elevation [25, 27] – both in-
cluded in our review – which showed improvements in
reflux symptoms and physiological intra-oesophageal pH
measures. A 2016 systematic review published in Chin-
ese, with a focus on patients experiencing reflux after
treatment for oesophageal cancer, similarly concluded
that head-of-bed elevation can improve reflux symptoms
[34]. Two more recent studies from 2019 [28] and 2020
[29] were included in our systematic review.
Implications for research and/or practice
The overuse of PPIs for gastroesophageal symptoms is a
health problem, and a clinical challenge for clinicians
globally. The findings of this review have confirmed that
elevating the head of the bed is a cheap, easy-to-
implement, relatively safe and promising approach. Im-
portantly we did not find evidence of no benefit from
this approach, but rather we found low quality evidence
of benefit. Given the need to reduce the overuse of un-
necessary medicines – with an unfavourable safety pro-
file [35]– clinicians must be able to offer evidence-based
non-pharmacological alternatives for treating these ex-
tremely common symptoms.
Additional quality randomized controlled trials evalu-
ating the effect of head-of-bed elevation as part of a
package of non-drug interventions in primary care set-
tings are warranted. Future trials need to be of rigorous
methodological quality with adequate sample size and
duration to detect clinically meaningful differences and
consistently measure and report patient-relevant out-
comes. As de-prescribing and other initiatives targeting
PPI overuse continue [1], offering clinicians and the
public alternative non-drug approaches becomes critical.
Conclusions
Methodological and reporting limitations in available lit-
erature preclude confident conclusions about the effect
of head of bed elevation in relieving gastroesophageal
symptoms. However, head of bed elevation could be still
considered as a cheap, relatively safe, and promising al-
ternative to drug interventions with unfavourable safety
profiles.
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